According to its severe respiratory viral infection and yearly epidemics and unexpected pandemics, influenza causes enormous morbidity and mortality. At the moment, neuraminidase inhibitors are a specific type of capsule used to treat influenza virus B infection (NAIs). The influenza virus B has carried extraordinary drug-resistant changes because to the widespread usage of NAI capsules. The purpose of this study is to provide guidance for scientific medicine by examining the treatment resistance mutations of the NA collection in Flu B. Influenza is an acute viral infection of the respiratory system that spreads from person to person, can affect any age group, and poses a serious threat to public health. Standard symptoms include a high temperature, runny nose, sore throat, headaches, coughing, and a generalised feeling of exhaustion. The World Health Organization (WHO), the USA Centers for Disease Control and Prevention, and other international fitness partners have just released updated estimates that as many as 650,000 people worldwide die from seasonal influenza-related respiratory diseases each year. According to virological taxonomy, the orthomyxoviride virus family includes the human influenza virus. The drug resistance mutations of influenza type B viruses had been accumulating due to type B influenza caused by the type B influenza virus and the widespread usage of NAI capsules. It has been hypothesised that influenza B viruses have evolved varying degrees of resistance to the aforementioned NAI capsules used in clinical settings. The drug resistance of NAI may not, however, be systematically observed worldwide. In order to characterise the significant drug resistance mutations in NA proteins and provide a theoretical foundation for improved medical prevention and manipulation of influenza B, we analysed the nearly full-length neuraminidase (NA) gene sequences of influenza Type B virus that were submitted to the global public database. In order to bind to NA and inhibit its active sites so that it cannot catalyse the hydrolysis of sialic acid and prevent the release of viral particles, NAIs can imitate the herbal substrate sialic acid. The influenza virus's RNA polymerase is susceptible to mismatches. As the scientific use of NAIs increased, the corresponding NAIs drug-resistant traces gradually emerged. It is now thought that the mutation of the viral RNA collection encoding NA, which modifies one or more amino acid residues comprising NA, is the molecular mechanism of influenza virus resistance to NAIs. The most frequent modifications involve the deletion and substitution of amino acid residues. Neuraminidase inhibitors, such as Oseltamivir, Zanamivir, Peramivir, etc., are currently the primary clinical medications for treating type B influenza. According to virological taxonomy, the orthomyxoviride virus family includes the human influenza virus. According to the antigenicity of its nuclear proteins, it is classified into A, B, and C types, with influenza B viruses serving as the main pathogens inflicting human influenza in recent years, with modest outbreaks in a few locations. Drug resistance is the decline in a medication's ability to effectively treat a condition or disease, such as an infection or cancer. When referring to resistance that viruses or malignancies have "acquired," that is, when resistance has evolved, the word is utilised. Research is sparked by the challenges posed by antimicrobial and anti-cancer resistance. A substance is said to as multidrug-resistant if it is resistant to multiple medications.